288 related articles for article (PubMed ID: 22348271)
1. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
McCarthy JR; Sazonova IY; Erdem SS; Hara T; Thompson BD; Patel P; Botnaru I; Lin CP; Reed GL; Weissleder R; Jaffer FA
Nanomedicine (Lond); 2012 Jul; 7(7):1017-28. PubMed ID: 22348271
[TBL] [Abstract][Full Text] [Related]
2. Detection and treatment of intravascular thrombi with magnetofluorescent nanoparticles.
Erdem SS; Sazonova IY; Hara T; Jaffer FA; McCarthy JR
Methods Enzymol; 2012; 508():191-209. PubMed ID: 22449927
[TBL] [Abstract][Full Text] [Related]
3. Novel and emerging therapies: thrombus-targeted fibrinolysis.
Lippi G; Mattiuzzi C; Favaloro EJ
Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
[TBL] [Abstract][Full Text] [Related]
4. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
5. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
[TBL] [Abstract][Full Text] [Related]
7. Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.
Stein-Merlob AF; Kessinger CW; Erdem SS; Zelada H; Hilderbrand SA; Lin CP; Tearney GJ; Jaff MR; Reed GL; Henke PK; McCarthy JR; Jaffer FA
Theranostics; 2015; 5(12):1317-27. PubMed ID: 26516370
[TBL] [Abstract][Full Text] [Related]
8. Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.
Sun M; Hao Pontius MH; Yang S; Pendekanti T; Raghunathan S; Shavit JA; Sen Gupta A
J Thromb Haemost; 2023 Apr; 21(4):983-994. PubMed ID: 36696210
[TBL] [Abstract][Full Text] [Related]
9. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
10. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Chen HA; Ma YH; Hsu TY; Chen JP
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
[TBL] [Abstract][Full Text] [Related]
11. Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.
Pitek AS; Wang Y; Gulati S; Gao H; Stewart PL; Simon DI; Steinmetz NF
Mol Pharm; 2017 Nov; 14(11):3815-3823. PubMed ID: 28881141
[TBL] [Abstract][Full Text] [Related]
12. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Marsh JN; Senpan A; Hu G; Scott MJ; Gaffney PJ; Wickline SA; Lanza GM
Nanomedicine (Lond); 2007 Aug; 2(4):533-43. PubMed ID: 17716136
[TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
16. Identification and Characterization of Plasmin-Independent Thrombolytic Enzymes.
Hassan MM; Sharmin S; Kim HJ; Hong ST
Circ Res; 2021 Feb; 128(3):386-400. PubMed ID: 33292062
[TBL] [Abstract][Full Text] [Related]
17. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging.
Robinson BR; Houng AK; Reed GL
Circulation; 2000 Sep; 102(10):1151-7. PubMed ID: 10973845
[TBL] [Abstract][Full Text] [Related]
18. A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Huang Y; Jiang J; Ren J; Guo Y; Zhao Q; Zhou J; Li Y; Chen R
Adv Healthc Mater; 2022 Oct; 11(19):e2201265. PubMed ID: 35864062
[TBL] [Abstract][Full Text] [Related]
19. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
20. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B
Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
